Will Hemophilia be next for the Clinic? Its Hemophilia A treatment could be next in line. Hemophilia A, also called factor VIII (FVIII) deficiency or classic hemophilia, is a genetic disorder caused by missing or defective factor VIII, a clotting protein. The disease occurs in 1 in 5,000 live male births and is about four times as common as hemophilia B. The number of people with hemophilia in world is not well known, but estimated at more than 400,000 people.
Medications to treat hemophilia cost an average of more than $270,000 annually per patient. Research estimates the global hemophilia market to be valued at US$11.1 billion in 2018.